Table 2. Comparison of outcomes .

Type	Follow-up duration (wk)	Abstinence rate		N; Risk ratio (95% CI)	P
		Herbal preparations	Placebo and other non-herbal Preparations
CAR	2	151/416	51/344	760; 1.15 (0.41-3.19)	0.022*
	4	148/416	48/344	760; 1.77 (0.52-4.11)	0.013*
	8	130/416	41/344	760; 2.13 (0.57-4.61)	0.011*
	10	9/32	2/32	64; 1.71 (0.41-1.17)	0.037*
	12	166/416	38/344	760; 2.72 (0.77-5.3)	0.014*
	24	16/32	1/32	64; 2.77 (0.37-1.13)	0.003*
PAR	2	153/416	52/344	760; 1.14 (0.42-3.19)	0.026*
	4	150/416	50/344	760;1.17 (0.61-4.55)	0.016*
	8	137/416	43/344	760; 1.24 (0.81-6.34)	0.022*
	10	11/28	1/28	64;1.66 (0.31-2.16)	0.031*
	12	169/416	37/344	760; 2.09 (0.93-8.29)	0.018*
	24	18/28	2/28	64;2.11 (0.31-3.08)	0.004*
Craving reduction	End of study	156/416	34/344	760; 2.13 (0.91-8.12)	0.0014*

* Significant.